Login
Toggle sidebar

Lint: antinuclear-antibody

antinuclear-antibody
Acronyms
warning

"Under indirect immunofluorescence (IIF) microscopy, four major ANA staining patterns are observed, due to the varying intranuclear distribution of antigenic targets 1:"

Line 3:67 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"a broad array of antigen specificities generates a speckled pattern, including those raised against U1-RNP, Sm, and La"

Line 12:111 · 'RNP' has no definition. Spell it out if it's unfamiliar to the audience.

"antibodies raised against components of the PM/Scl and 7-2RNP complexes; U3RNP (fibrillarin); RNA polymerases; and Scl70 (topoisomerase I)"

Line 22:56 · 'PM' has no definition. Spell it out if it's unfamiliar to the audience.

"antibodies raised against components of the PM/Scl and 7-2RNP complexes; U3RNP (fibrillarin); RNA polymerases; and Scl70 (topoisomerase I)"

Line 22:106 · 'RNA' has no definition. Spell it out if it's unfamiliar to the audience.

"ANAs are implicated in the pathophysiology of numerous diseases, including many inflammatory rheumatic diseases. The ANA IIF assay is highly sensitive but minimally specific; low-titre positive ANA results occurs in approximately 13.8% of the general population 2, though some studies report up to 40% prevalence 3. This fact lacks any well-described clinical consequences 4."

Line 25:121 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"ANAs are implicated in the pathophysiology of numerous diseases, including many inflammatory rheumatic diseases. The ANA IIF assay is highly sensitive but minimally specific; low-titre positive ANA results occurs in approximately 13.8% of the general population 2, though some studies report up to 40% prevalence 3. This fact lacks any well-described clinical consequences 4."

Line 25:198 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"Loose associations are often made between particular ANA staining patterns and likely underlying autoimmune disorders, but no pattern is completely specific for any single disease. Following a positive ANA result, solid phase assays may be used to detect specific disease-associated autoantibody subtypes to aid in diagnosis."

Line 27:57 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"Loose associations are often made between particular ANA staining patterns and likely underlying autoimmune disorders, but no pattern is completely specific for any single disease. Following a positive ANA result, solid phase assays may be used to detect specific disease-associated autoantibody subtypes to aid in diagnosis."

Line 27:206 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"Grouped by IIF staining pattern, diseases associated with positive ANA titre include 5:"

Line 28:71 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"U1-RNP"

Line 92:7 · 'RNP' has no definition. Spell it out if it's unfamiliar to the audience.

"MCTD (95-100% in high titre with no other ANA subtype present)"

Line 94:50 · 'ANA' has no definition. Spell it out if it's unfamiliar to the audience.

"SS-A (Ro)"

Line 102:4 · 'SS-A' has no definition. Spell it out if it's unfamiliar to the audience.

"SS-B (La)"

Line 114:4 · 'SS-B' has no definition. Spell it out if it's unfamiliar to the audience.
Heterogeneous Spelling
warning

"homogenous"

Line 6:4 · Radiopaedia advises the '-eous' form: 'homogeneous' rather than 'homogenous'.

"homogenous"

Line 31:4 · Radiopaedia advises the '-eous' form: 'homogeneous' rather than 'homogenous'.
List Caps
warning

"Sm"

Line 85:4 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

"Scl-70"

Line 137:4 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

"Jo-1"

Line 145:4 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Associations"

Line 26:1 · "Associations" is under the wrong parent heading (found under "Pathology").
Oxford Comma
suggestion

"antibodies raised against centromere proteins A, B and C"

Line 18:58 · Use the Oxford comma in 'A, B and C'.
Semicolons
suggestion

"antibodies raised against components of the PM/Scl and 7-2RNP complexes; U3RNP (fibrillarin); RNA polymerases; and Scl70 (topoisomerase I)"

Line 22:83 · Use semicolons judiciously.

"antibodies raised against components of the PM/Scl and 7-2RNP complexes; U3RNP (fibrillarin); RNA polymerases; and Scl70 (topoisomerase I)"

Line 22:104 · Use semicolons judiciously.

"antibodies raised against components of the PM/Scl and 7-2RNP complexes; U3RNP (fibrillarin); RNA polymerases; and Scl70 (topoisomerase I)"

Line 22:121 · Use semicolons judiciously.

"ANAs are implicated in the pathophysiology of numerous diseases, including many inflammatory rheumatic diseases. The ANA IIF assay is highly sensitive but minimally specific; low-titre positive ANA results occurs in approximately 13.8% of the general population 2, though some studies report up to 40% prevalence 3. This fact lacks any well-described clinical consequences 4."

Line 25:177 · Use semicolons judiciously.

"PSS (15-43%); associated with more severe organ involvement (e.g. pulmonary fibrosis) 4"

Line 138:24 · Use semicolons judiciously.

"polymyositis (30%); particularly associated with interstitial lung disease 4"

Line 146:37 · Use semicolons judiciously.
Links
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0